Back to search results

Virtual Reality for Functional Dyspepsia

This study is looking into whether virtual reality can help treat the stomach and gut symptoms of functional dyspepsia (a common condition causing ongoing indigestion without a clear cause). You might be able to join if you are between 18 and 75 years old, have functional dyspepsia based on specific medical criteria, and have had an upper endoscopy. If you had H. pylori (a type of bacteria) detected, it must have been treated and confirmed gone before you can join. The main goal is to see how much your abdominal pain scores change after 8 weeks of treatment. The study is currently unclear on its recruitment status and plans to enroll 30 participants.

Study design
This is an interventional study with an estimated enrollment of 30 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your abdominal pain scores will be measured at baseline and again at 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05836597

Functional Dyspepsia Treatment Using Virtual Reality

Recruiting
NAAges 18–75InterventionalTreatment
Mayo Clinic
~30 participants
Updated 2026-01-22 on ClinicalTrials.gov
What's tested:Virtual reality

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in abdominal pain scores
Measured over Baseline, 8 weeks

Conditions

Functional Dyspepsia

Explore related trials

Nonulcer dyspepsia

NCT05836597

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Florida

    Jacksonville, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • David Cangemi · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

David Cangemi, MD
[email protected]
904-953-2000
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Symptoms of dyspepsia thought to represent functional dyspepsia, meeting Rome IV criteria
Had an upper endoscopy and assessment for Helicobacter pylori; if a patient is found to have H. pylori, treatment with confirmed eradication (by stool antigen test or urea breath test) will be required before the patient is eligible for study inclusion.
Patients will be considered for the study if they have undergone a complete history and physical examination during a previously scheduled consultation/evaluation visit with a gastroenterologist in the Mayo Clinic Florida General GI or Motility clinic.

Exclusion

Symptoms are thought to represent an organic disorder (e.g., peptic ulcer disease, hepatitis, pancreatitis, inflammatory bowel disease, type I diabetes, a known malignancy, radiation-induced injury, an active infection, vasculitis, celiac disease), or patients have known uncontrolled GERD, esophagitis, eosinophilic esophagitis, or untreated H. pylori.
Patients with gastroparesis or cyclic vomiting syndrome.
Patients with prior surgery to the esophagus, stomach or duodenum.
Patients taking opioids.
Patients with motion sickness, vertigo, or a seizure disorder
IBS symptoms are not predominant.

What this trial measures

  • Change in abdominal pain scoresBaseline, 8 weeks

    Measured by the Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) questionnaire individual scores for abdominal pain. Scored 0-5, with higher scores representing more severe symptoms.